Serum EV-derived lncRNA DLX6 antisense RNA 1 (DLX6-AS1) was found to be elevated in 72 NSCLC patients compared to their 64 healthy controls and could be a promising diagnostic marker with AUC of 0.806.148 Not only was this lncRNA elevated in lung cancer patients in TCGA datasets, but more importantly, DLX6-AS1 levels in serum dynamically decreased post-operatively after tumor excision, suggesting that the enrichment of this lncRNA could be tumor-associated. This evidence concerns the gene DLX6 and lung cancer.